Lantern Pharma Inc. (NASDAQ: LTRN) has recently appointed Dr. Lee T. Schalop, MD, a seasoned biotech executive and Wall Street analyst, to its Board of Directors. Dr. Schalop’s extensive experience in biotechnology leadership and financial markets, particularly in precision neurooncology and clinical development, makes him a valuable addition to Lantern Pharma’s team.
With a successful track record in building and scaling precision oncology companies, Dr. Schalop’s expertise aligns perfectly with Lantern Pharma’s AI-driven approach to targeting challenging cancers. His strategic insight and experience in navigating complex clinical pathways are expected to drive Lantern Pharma’s mission of transforming cancer drug discovery and development through artificial intelligence and machine learning.
Read more from finance.yahoo.com